A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia by Losordo, Douglas W. et al.
A Randomized, Controlled Pilot Study of Autologous CD34+ Cell
Therapy for Critical Limb Ischemia
Douglas W. Losordo, MD*, Melina R. Kibbe, MD¥, Farrell Mendelsohn, MD†, William
Marston, MD‡, Vickie R. Driver, DPM MS§, Melhem Sharafuddin, MD∞, Victoria Teodorescu,
MD#, Bret N. Wiechmann, MD**, Charles Thompson, MD††, Larry Kraiss, MD‡‡, Teresa
Carman, MD§§, Suhail Dohad, MD∞∞, Paul Huang, MD##, Candice E. Junge, PhDπ, Kenneth
Storyπ, Tara Weistroffer*, Tina M. Thorne*, Meredith Millay*, John Paul Runyon, MD¥¥, and
Robert Schainfeld, DO║ for the ACT34-CLI Investigators
*Division of Cardiovascular Medicine, Northwestern Memorial Hospital and Feinberg
Cardiovascular Research Institute, Northwestern University
¥Divisions of Cardiology and Vascular Surgery, Northwestern Memorial Hospital, Northwestern
University, Chicago, IL
†Center for Therapeutic Angiogenesis, Birmingham, AL
‡University of North Carolina Division of Vascular Surgery Chapel Hill, NC
§Department of Surgery, Boston Medical Center and Boston University School of Medicine
Boston, MA
∞University of Iowa Department of Surgery Iowa City, IA
#Mount Sinai School of Medicine Division of Vascular Surgery New York, NY
**Vascular and Interventional Physicians, Gainesville, FL
††Orlando Regional Medical Center Vascular Specialist of Central FL Orlando, FL
‡‡University of Utah Division of Vascular Surgery Salt Lake City, UT
§§University Hospitals Case Medical Center Cleveland, OH
∞∞Cedars-Sinai Medical Center, Los Angeles, CA
##Swedish Medical Center Seattle, WA
πBaxter Healthcare, Deerfield, IL
¥¥Christ Hospital Cincinnati, Ohio
║Massachusetts General Hospital, Boston, MA
Abstract
Correspondence to: Douglas W. Losordo, MD, Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015, Phone:
(847)948-3197, Fax: (847)948-2181, douglas_losordo@baxter.com.
Disclosures: Douglas W. Losordo, Candice E. Junge and Kenneth Story are employed by Baxter Healthcare Corporation.
Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00616980
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Circ Cardiovasc Interv. Author manuscript; available in PMC 2013 December 01.
Published in final edited form as:











Background—Critical limb ischemia (CLI) portends a risk of major amputation of 25-35%
within 1 year of diagnosis. Pre-clinical studies provide evidence that intramuscular injection of
autologous CD34+ cells improve limb perfusion and reduce amputation risk. In this randomized,
double-blind, placebo-controlled pilot study, we evaluated the safety and efficacy of intramuscular
injections of autologous CD34+ cells in subjects with moderate or high-risk CLI who were poor or
non-candidates for surgical or percutaneous revascularization (ACT34-CLI).
Methods and Results—Twenty-eight CLI subjects were randomized and treated: 7 to 1×105
(low-dose) and 9 to 1×106 (high-dose) autologous CD34+ cells/kg; 12 to placebo (control).
Intramuscular injections were distributed into 8 sites within the ischemic lower extremity. At 6
months post-injection 67% of control subjects experienced a major or minor amputation versus
43% of low-dose and 22% of high-dose cell-treated subjects (P=0.137). This trend continued at 12
months with 75% of control subjects experiencing any amputation versus 43% of low-dose and
22% of high-dose cell-treated subjects (P=0.058). Amputation incidence was lower in the
combined cell-treated groups compared with control group (6 months: P=0.125; 12 months:
P=0.054), with the low-dose and high-dose groups individually showing trends towards improved
amputation free survival at 6 and 12 months. No adverse safety signal was associated with cell
administration.
Conclusions—This study provides evidence that intramuscular administration of autologous
CD34+ cells was safe in this patient population. Favorable trends toward reduced amputation rates
in cell-treated versus control subjects were observed. These findings warrant further exploration in
later phase clinical trials.
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The age-adjusted prevalence of peripheral arterial disease (PAD) in the U.S. population has
been estimated to approach 12%.(1) The clinical consequences of symptomatic occlusive
peripheral arterial disease (PAD) include intermittent claudication (IC), i.e., pain with
walking, and critical limb ischemia (CLI), which includes pain at rest and loss of tissue
integrity in the distal limbs, i.e., non-healing ulcers or gangrene.(2,3) The worldwide
incidence of CLI is estimated to be 500 to 1000 cases per million people per year.(2)
The first objective in treating CLI is to increase perfusion to the affected limb. Surgical
bypass techniques and percutaneous catheter-based interventions have both been used to
successfully revascularize the limbs of patients with CLI. In many patients, however,
heanatomic extent and distribution of arterial occlusive disease is too severe or advanced to
permit relief of pain and/or facilitate healing of ischemic ulcers. It is estimated that up to
50% of CLI patients are not suitable candidates for surgical options.(4) No effective medical
therapy is available for the treatment of such patients.
The rationale for this clinical study is based upon preclinical studies of CD34+ cell
transplantation using in vivo models of hind limb ischemia which demonstrated that
intramuscular administration of human CD34+ cells could augment perfusion and reduce the
incidence of amputation.(5,6) We evaluated the safety and potential efficacy of intramuscular
injection of autologous CD34+ cells in subjects with moderate or high-risk CLI who were
poor or non-candidates for surgical or percutaneous revascularization (ACT34-CLI).
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The ACT34-CLI study was a prospective, double-blind, randomized, placebo-controlled
clinical pilot study conducted at 14 centers in the United States. A total of 28 subjects were
randomized 1:1:1 to 3 treatment groups: low-dose (1×105 Auto-CD34+ cells/kg, N=7), high-
dose (1×106 Auto-CD34+ cells/kg, N=9), and control (placebo, N=12). The objectives of
this Phase I/IIa clinical trial were to evaluate the safety and bioactivity of intramuscular
injection of Auto-CD34+ cells in subjects with Rutherford Categories 4 and 5 who were not
amenable to percutaneous or surgical revascularization. The institutional review board at
each center approved the protocol, and all subjects provided written informed consent. The
principal investigator (D. Losordo) was the IND holder and had responsibility for the
conduct of the study, and Baxter Healthcare funded the study. Safety data were monitored
by an independent Data Safety Monitoring Board.
Study Population
Male or female patients aged 21 years or older with Rutherford categories 4 or 5 CLI and no
suitable revascularization options (determined by independent vascular surgeons and
vascular interventionists) were eligible for this study. In addition, demonstrated infra-
inguinal atherosclerosis with a stenosis (>70%) or occlusion (100%) of a major vessel and
an absolute ankle pressure in the affected limb of <60 mmHg or a reduced toe pressure of
<40 mmHg or abnormal PPG, diagnostic of microvascular insufficiency (flat wave forms)
were required.
Candidates were excluded* if arterial insufficiency in the lower extremity was the result of a
non-atherosclerotic disorder, including but not limited to, advanced scleroderma (CREST
syndrome). Additional exclusion criteria included patients with advanced CLI (Rutherford
Category 6), expected amputation within 4 weeks of screening, clinical evidence of sepsis,
advanced AV block or NYHA Class III or Class IV heart failure, myocardial infarction
within 3 months, or clinically successful aortic or lower extremity arterial surgery,
percutaneous revascularization, or lumbar sympathectomy within 3 months preceding
screening.
Auto-CD34+ Cell Mobilization, Collection, and Preparation
To maintain the double-blind design, all subjects underwent cell mobilization with 5 μg/kg
per day doses of granulocyte colony stimulating factor (G-CSF) (Filgrastim/Neupogen®,
Amgen, Thousand Oaks, CA) administered subcutaneously for 4 or 5 days followed by
leukapheresis on the fifth day. The following day, the leukapheresis product was enriched
for CD34+ cells using the ISOLEX 300i Magnetic Cell Selection System (Baxter
Healthcare, Deerfield, IL). Lot release testing was performed on the final cell preparation to
document sterility (gram stain and subsequent culture), viability (7-AAD apoptosis
staining)(7) and purity (fluorescence activated cell sorting for CD34+ cells). Auto-CD34+
cells were suspended in 4 mLs of 0.9% NaCl (saline) plus 5% autologous plasma and
provided to the investigator in 8 syringes.
Randomization and Blinding
Once the cell product passed all lot release criteria, the subject was randomized to 1 of the 3
treatment arms. Subjects were prospectively stratified centrally for Rutherford category 4 or
5, presence or absence of diabetes mellitus, and smoker or non-smoker. The investigator,
*Thromboangiitis obliterans (Buerger's Disease) was allowed
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subject, study site personnel, core laboratory(ies), blinded study statistician, and all Sponsor
and CRO personnel remained blinded to all subject treatment.
Cell Injection Procedure
On the day of randomization, the total cell dose was delivered via intramuscular injection
into 8 distinct sites (0.5 mL/site) in the ischemic lower extremity using a 1 mL syringe fitted
with a 27 gauge needle. In the majority of subjects in which ischemia was most prominently
manifested in the distal lower extremity (below knee), the 8 injections were distributed in
the proximal, mid and distal calf, according to the subject's clinical status and vascular
anatomy, targeting ischemic muscle supplied by occluded or stenotic arteries.
Endpoints
Safety—The primary endpoint of this exploratory study was the safety of intramuscular
injection of Auto-CD34+ cells. Adverse events (AEs), vital signs, and laboratory
assessments (clinical chemistry, hematology, cardiac biomarkers and urinalysis) were
assessed during the treatment period (G-CSF cell mobilization, apheresis and intramuscular
injection) and during the follow-up period at weeks 2, 4, 6, 8 and 12 weeks and 6 and 12
months.
Efficacy—To assess limb salvage, the occurrence of amputation, nature of amputation (toe
or transmetatarsal, below or above knee, preserving or not preserving function), and time to
amputation were recorded during the 12 month follow-up period.
A subject diary was used to record rest pain. Subjects began recording rest pain in their
diaries 7 days prior to each follow-up visit. Changes from baseline in the duration,
frequency and intensity (numerical rating pain scale from 1 [least pain] to 10 [greatest pain])
of rest pain, analgesic use, and sleep history were assessed.
The Six Minute Walk test was performed at baseline, week 12, and months 6 and 12 to
assess functional improvement in subjects. The Modified Borg Scale was used to measure
fatigue and a baseline score was determined before beginning the test. All symptoms,
walking distance, time to onset of leg cramping/pain were recorded.
A core lab (Canfield) was utilized for wound assessment. Assessment included ulcer tracing
and photography of the wound. Acetate tracings of the wound and digital planimetry were
used to assess changes from baseline in ulcer size (area). Time to complete healing or
change to a state of potentially successful surgical closure or skin grafting was recorded.
Quality of life (QoL) was assessed using the SF-36 QoL questionnaire (version 1).
Disease severity was assessed by changes from baseline in the Rutherford Clinical Severity
score, absolute ankle and toe pressure, and ankle and toe brachial index (ABI and TBI,
respectively).
Statistical Analysis
This study was designed to help determine the selection of endpoints, time points and the
appropriate sample sizes for subsequent clinical studies of Auto-CD34+ cells for subjects
with CLI. All analyses performed were intent to treat. Efficacy analyses were exploratory in
nature and no corrections for multiple comparisons or formal sample size calculations were
performed. Baseline characteristics were summarized. One-way ANOVA was used to test
for differences in the treatment groups for continuous variables and Fisher's exact test was
used for categorical variables. AEs were summarized. Fisher's exact test was used to test for
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differences between treatment groups in percent of subjects with amputations. Log-Rank
tests were used to test for differences in the distributions of time to first amputation. The
adjusted amputation rates were calculated assuming that amputations have a negative
binomial distribution. Changes in function and disease severity over time are presented
descriptively; no statistical analysis was performed.
Results
Subject Disposition and Baseline Characteristics
Between November 2007 and April 2010, 14 centers across the United States screened 43
subjects; 28 subjects met the entry criteria for this study and underwent G-CSF cell
mobilization, apheresis to collect total mononuclear cells, randomization and intramuscular
injections of Auto-CD34+ cells or placebo (Figure 1). In total 20 subjects completed the 1
year study follow-up period.
There were no statistically significant differences in subject baseline demographics, medical
history and disease characteristics between treatment groups (Table 1). The study population
included 9 females and 19 males with a mean age of 67 years. Previous lower extremity
bypass surgery or PCI had been performed in all subjects.
Safety of Auto-CD34+ Cell Therapy during Treatment and Follow-up Period
A total of 60 serious AEs (SAEs) in 22 (79%) subjects occurred during the study of which
59 occurred after intramuscular injection and 1 occurred during mobilization. The majority
of SAEs were considered unrelated to study treatment by the investigator with the exception
of 2 SAEs which were considered possibly study-related: 1 subject experienced moderate
hypotension during mobilization which required prolonged hospitalization, and 1 subject
experienced severe worsening of CLI in the target leg after injection which required
prolonged hospitalization. Only 1 SAE was cardiac-related: 1 subject in the control group
experienced an acute non-ST segment elevation MI approximately 4.5 months post-
injection. There were 2 deaths during the study which were not considered study-related and
these were the only subjects to discontinue due to an AE.
Predominantly modest and exclusively asymptomatic elevations in cardiac enzyme levels
were observed during the mobilization (G-CSF) and injection period (Table 2). Of the
subjects with cardiac enzyme measurements, elevated troponin, CK-MB and CK levels (> 1
× ULN) were observed in 9 (56.3%), 13 (54.2%) and 4 (15.4%) of subjects, respectively,
during the mobilization and injection period. During the follow-up period, elevated troponin,
CK-MB and CK levels (> 1 × ULN) were observed in 5 (27.8%), 8 (30.8%) and 5 (17.9%)
of subjects, respectively.
Amputation
All efficacy analyses were exploratory in nature as the study was not powered to detect
differences among treatment groups in efficacy parameters. At 6 months post-injection, 8
(66.7%) subjects in the control group, 3 (42.9%) subjects in the low-dose group and 2
(22.2%) subjects in the high-dose group experienced an amputation (P = 0.137, Table 3).
Major amputations occurred in 4 subjects in the control group, in 3 subjects in the low dose
group and 2 in the high dose group (P=0.780). At 12 months post-injection there was no
increase in the incidence of amputations in the cell-treated groups from the 6-month post-
injection time point, but the incidence increased slightly in the control group (9 [75.0%]
subjects; P=0.058). The incidence of major amputations was slightly higher in the control
group (N=6 [50%]) compared with the cell-treated groups, but this difference was not
statistically significant (P = 0.488). Trends toward lower amputation rates in the cell-treated
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groups versus the control group were observed at 6 months (P=0.187) and 12 months post-
injection (P=0.121). Statistically significant differences in major amputation rates among the
control and cell-treated groups at 6 months (P = 0.303) and 12 months (P = 0.430) post-
injection were not detected.
When subjects in the cell-treated groups are combined, the incidence of total amputations at
6 months and 12 months post-injection was 66.7% in control versus 31.3% in cell-treated
subjects (P=0.125) and 75.0% in control versus 31.3% in cell-treated subjects (P=0.054),
respectively. The incidence of major amputations at 6 months and 12 months post-injection
was 33.3% in control versus 31.3% in cell-treated subjects (P=1.000) and 50.0% in control
versus 31.3% in cell-treated subjects (P=0.441), respectively.
There were trends toward an increased probability of amputation free survival in the low-
dose and high-dose groups compared with the control group during 12 month post-injection
follow-up period (P=0.35, Log Rank Test, Figure 2a). When the cell-treated groups are
combined, the probability of amputation free survival was significantly increased in the cell-
treated group compared with the control group (P=0.013; Figure 2b). A trend toward
improved major amputation free survival was observed in the individual cell-treated groups
(Figure 2c) and combined cell-treated group (Figure 2d) compared with the control group
(P=0.414 and P=0.294, respectively).
Functional Improvement, Wound Healing, and Rest Pain
Of the 28 subjects enrolled in the study, 22 completed the 6 minute walk test at baseline
(Table 4). A total of 11 subjects completed the 6 minute walk test at the 6 and/or 12 month
post-injection timepoints (Figure 3). In the control group (N=4), the distance walked
increased for 2 subjects and decreased for 2 subjects. In the cell-treated groups (N=7), the
distance walked increased for 6 subjects and decreased slightly for 1 subject. Eleven
subjects did not complete the test at 6 and 12 months post-injection for the following
reasons: amputation (N=7), withdrawal from study (N=3) and unknown (N=1).
A total of 14 subjects had leg ulcers at baseline (Table 4). At 6 months post-injection,
wound area measurements were not reported in 5 of the 14 subjects with ulcers at baseline
due to amputation (Figure 3). At 12 months post-injection, wound area measurements were
not reported in an additional 4 subjects due to subject withdrawal (N=2) or assessment not
performed (N=2). There were no treatment-related trends in terms of wound healing
observed at 6 months or 12 months post-injection.
A total of 27 subjects completed the pain diary at baseline. Overall, decreases in the median
number of pain episodes per week and the average pain intensity scores were observed in all
groups at 6 months and 12 months post-injection (Table 4).
Disease Severity
There were minor fluctuations in the ABI and TBI among subjects in all treatment groups
with preserved limbs and measurements at 6 and 12 months (Table 5). Of the subjects with
Rutherford score data at 6 months and 12 months post-injection (N=13 and N=11,
respectively), the mean Rutherford score decreased from baseline in all treatment groups at
6 months post-injection and in the control and high-dose groups at 12 month post-injection.
The mean Rutherford score in the low-dose group remained unchanged from baseline at 12
months post-injection.
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At 6 months post-injection, improvements from baseline in the majority of health domain
scores were observed in all treatment groups (Figure 4). At 12 months post-injection,
improvements in the mean scores were observed in 8, 5 and 3 of the health domains in the
low-dose, high-dose and control groups, respectively.
Discussion
The results from this Phase I/IIa pilot study provide initial evidence that intramuscular
injection of Auto-CD34+ cells is safe and well-tolerated in patients with moderate or high-
risk CLI who are poor or non-candidates for surgical or percutaneous revascularization.
Trends toward decreased amputation in Auto-CD34+ cell-treated subjects compared with
control subjects demonstrate the potential efficacy of Auto-CD34+ cell therapy in this
population. One must use caution in interpreting these results, however, since a higher
percentage of subjects experienced amputations during this study relative to other recent
clinical studies of CLI.(8,9,10,11,4)
Several surrogate markers (ABI, TBI, leg pain, walking distance, wound healing) of limb
perfusion were explored and no differences were detected between the cell-treated and
control groups; however, this study was not powered to detect differences in efficacy
endpoints. In addition, the high rate of amputation observed in this study resulted in missing
data for several of these endpoints, making it difficult to draw any conclusions. No
differences in QoL were detected among the cell-treated and control groups.
In theory, increased blood flow could be achieved by increasing the number of vessels that
supply the ischemic tissue with blood. The use of pharmacological or biological therapies to
induce new blood vessel growth for the treatment or prevention of pathological clinical
conditions has been termed therapeutic angiogenesis.(12,13) The mechanism of action for the
majority of pharmacological therapies tested for CLI is vasodilation and promotion of
angiogenesis with agents such as prostaglandins. Two randomized, double-blind, phase 3
studies of lipo-ecraprost as a parenteral therapy or as an adjunctive parenteral therapy after
distal revascularization in subjects with CLI did not, however, improve major amputation or
survival outcomes.(9,10)
Biological therapies, including gene therapy and stem cell therapy, have been evaluated in
patients with CLI for improving perfusion in ischemic tissues.(14,15,16,17,11,18,19) Stem cell
therapy for the treatment of CLI is an emerging therapy in which unselected bone marrow
mononuclear cells (BM-MNC) or BM-MNC selected to express particular cell surface
markers are delivered via intramuscular or intraarterial injection. While a limited number of
blinded, randomized controlled trial (RCTs) evaluating cell therapy for no-option CLI
patients have been performed, results from several early phase studies show no safety signal
and demonstrate favorable trends in efficacy parameters for cell-treatment versus control. In
the TACT study a significant increase in ABI and TcPO2 was observed in subjects treated
with BM-MNC compared with those treated with peripheral blood MNC.(20) Interim results
from RESTORE-CLI, a blinded RCT in which bone marrow aspirate was processed to
generate the tissue-repair cell (TRC) population of stem and progenitor cells, demonstrated
that TRC-treated subjects had increased amputation free survival and time to treatment
failure compared with placebo subjects.(21) Treatment with BM-MNCs in the PROVASA
trial was associated with improved ulcer healing and reduced rest pain compared with
placebo.(22) A recent report of 12-week data from a RCT of bone marrow aspirate
concentrate (BMAC) demonstrated favorable trends for BMAC versus control in major
amputations and improved pain, ABI, Rutherford classification and QoL.(23) The results of
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these studies are encouraging; however, the variability between studies in the efficacy
endpoints that detected differences between the cell-treated and control groups highlight the
challenges of choosing clinically meaningful measures of efficacy in this population.
In our study we chose to isolate and administer CD34+ cells for 2 principal reasons: 1 -
because of their demonstrated pro-angiogenic potential in vivo, (5,6) and 2- because an
available, approved technology permitted the “manufacturing” of CD34+ cell preparations
by standardized methods. The advantage of this approach is that selection of CD34+ cells
results in a higher concentration of endothelial progenitor cells in each dose compared with
unselected MNCs resulting in greater therapeutic potency in preclinical models. There are
no known disadvantages of this approach other than the added step in cell processing. A
theoretical disadvantage of this approach is the possibility that other cell types, which may
exert pro-angiogenic or reparative functions, are removed; however the evidence from pre-
clinical models does not support this concept. Similar to the studies described above, we
observed favorable trends in efficacy including reduced amputation rates and improved
amputation free survival in the cell-treated groups compared with the control group. The
high rate of amputations observed in our study, however, limited the interpretation of other
efficacy endpoints.
Taken together, the results from our pilot study and other early stage studies provide
evidence for the safety and potential bioactivity of stem cell therapy for CLI. Multiple early
phase studies of additional stem cell therapies are currently underway.(24) Large
randomized, placebo-controlled, double-blind studies are necessary; however the high cost
of conducting trials in this patient population remains a significant challenge, particularly for
earlier stage companies attempting to develop novel therapeutics. In addition, the large
variability observed in amputation rates in the phase 2 and phase 3 studies of FGF1 gene
therapy(8,17) suggests that a better understanding of the no-option CLI population is
necessary such that patient demographics, physiological characteristics, biomarkers or yet to
be defined genetic markers can be used to better predict event rates in this population.
In conclusion, the overall positive safety profile of collecting and administering autologous
CD34+ cells in this patient population as well as the potential efficacy of preventing
amputations warrant larger scale studies to verify these findings, and to further refine the
methods for collecting and administering Auto-CD34+ cells to patients with disabling CLI.
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Human CD34+ cells are well known as hematopoietic stem cells used for stem cell
transplants in patients who have bone marrow ablation by chemotherapy or radiation
therapy.
Preclinical studies in models of myocardial or limb ischemia show that local delivery of
human CD34+ cells improves perfusion and function in ischemic tissue.
What this article adds
In a double-blind, randomized, placebo controlled pilot clinical trial in patients with
Rutherford Class 4 and 5 critical limb ischemia, direct intramuscular injection of
autologous CD34+ cells was associated with reductions in the frequency of amputation.
The strategy of mobilizing and collecting autologous CD34+ cells in CLI patients was
shown to be feasible and was not associated with an adverse safety signal. Further study
is warrented.
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Figure 1. Study Design and Subject Disposition
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Figure 2. Probability of Amputation Free Survival
Probability of amputation free survival in low-dose, high-dose and control groups (A) and in
combined cell-treated and control groups (B). Probability of major amputation free survival
in low-dose, high-dose and control groups (C) and in combined cell-treated and control
groups (D).
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Figure 3. Functional Improvement and Wound Healing at 6 and 12 Months
3A: Total distance walked on 6 minute walk test at baseline and 6 and 12 months post-
injection in subjects that completed the test at 6 and/or 12 months post-injection. 3B: Total
wound area in the treated leg in subjects with ulcers reported at 6 and/or 12 months post-
injection. Zero (0) indicates no leg ulcer present. C=control, L=low-dose, H=high-dose,
WD=withdrawal, A=amputation, M=missing.
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Figure 4. Summary of Mean Change from Baseline in SF-36 Health Domains
Mean (±SD) change from baseline in SF-36 health domains at 6 months and 12 months post-
injection. PF=physical functioning, RP=role physical, BP=bodily pain, GH=general health,
V=vitality, SF=social functioning, RE=role emotional, MH=mental health, HT=health
transition.
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Table 1
Baseline Characteristics of Study Population
Control (N=12) 1×05 c/kg (N=7) 1×106 c/kg (N=9) P-value
Demographics
 Age (mean ± SD) 67.1 ± 14.2 61.8 ± 13.9 69.7 ± 10.9 0.497
 Female (%) 50.0 28.6 11.1 0.180
 BMI (mean ± SD) 27.0 ± 4.7 29.3 ± 6.0 31.0 ± 7.9 0.348
PAD Risk Factors
 Hypertension (%) 83.3 85.7 77.8 1.000
 Current, Former Smoker (%) 8.3, 58.3 57.1, 42.9 33.3, 44.4 0.179
 Diabetes (%) 41.7 71.4 55.6 0.446
 Hyperlipidemia (%) 58.3 57.1 66.7 1.000
 Buerger's Disease (%) 0.0 14.3 0.0 0.250
Previous Vascular Interventions
 Prior Bypass Graft (%) 58.3 71.4 44.4 0.495
 Prior Angioplasty (%) 58.3 57.1 55.6 1.000
 Prior Endarterectomy (%) 33.3 14.3 11.1 0.507
 Prior Stent Placement (%) 58.3 42.9 66.7 0.716
Concomitant Cardiovascular Disease
 Angina Pectoris (%) 16.7 0.0 0.0 0.492
 Myocardial Infarction (%) 25.0 14.3 22.2 1.000
 Congestive Heart Failure (%) 8.3 14.3 33.3 0.390
 Coronary intervention (%) 41.7 42.9 44.4 1.000
 Stroke (%) 8.3 0.0 0.0 1.000
 Pulmonary embolism (%) 0.0 14.3 0.0 0.250
Medications
 Beta Blocker (%) 33.3 42.9 66.7 0.390
 Ca2+ Blocker (%) 16.7 71.4 33.3 0.076
 ASA (%) 83.3 71.4 66.7 0.645
 Clopidogrel (%) 58.3 57.1 33.3 0.623
 Statin (%) 83.3 71.4 88.9 0.690
 ACE-inhibitor/ARB (%) 58.3 71.4 55.6 0.790
Vascular Measures
*
 Absolute Ankle Pressure (mean ± SD) 0.37 ± 0.20 0.50 ± 0.32 0.48 ± 0.23 0.487
 Toe Pressure (mean ± SD) 0.07 ± 0.10 0.30 ± 0.48 0.28 ± 0.39 0.326
 Ischemic Rest Pain (Rutherford 4, [% ]) 41.7 57.1 55.6 0.746
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Control (N=12) 1×05 c/kg (N=7) 1×106 c/kg (N=9) P-value
 Minor Tissue Loss (Rutherford 5, [% ]) 58.3 42.9 44.4
*
In affected limb
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Table 3
Summary and Analysis of All Amputations by Treatment Group
Control (N=12) 1×105 c/kg (N=7) 1×106 c/kg (N=9) P-Value
6 Months
 % with Amputation (N) 66.7% (8) 42.9% (3) 22.2% (2) 0.137
 % with Major Amputation (N) 33.3% (4) 42.9% (3) 22.2% (2) 0.780
 Total Number of Amputations 9 5 2
 Adjusted Amputation Rate* (Lower, Upper 95% CI) 1.50 (0.78, 2.87) 1.42 (0.59, 3.42) 0.44 (0.11, 1.77) 0.187
 Adjusted Major Amputation Rate* (Lower, Upper 95% CI) 0.66 (0.25, 1.77) 1.42 (0.59, 3.42) 0.44 (0.11, 1.77) 0.303
12 Months
 % with Amputation (N) 75.0% (9) 42.9% (3) 22.2% (2) 0.058
 % with Major Amputation (N) 50.0% (6) 42.9% (3) 22.2% (2) 0.488
 Total Number of Amputations 12 5 2
 Adjusted Amputation Rate* (Lower, Upper 95% CI) 1.00 (0.57, 1.76) 0.72 (0.30, 1.73) 0.26 (0.06, 1.03) 0.121
 Adjusted Major Amputation Rate* (Lower, Upper 95% CI) 0.50 (0.22, 1.11) 0.72 (0.30, 1.73) 0.26 (0.06, 1.03) 0.430
*
Amputations per year. Adjusted for different rates for each subject using Negative Binomial model.
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